[Clinical picture of acute myocardial infarction depending on the use of pharmacologic treatment schemes].
The aim of the work was a retrospective comparison of the clinical course of acute myocardial infarction depending on the applied schema of pharmacological treatment: streptokinase, heparin, antiplatelet drugs. The analysis included 409 patients (261 men and 148 women aged 31-85 years; mean age 61 years). Twelve-lead ECG records were analysed: 24 hours, 48 hours, 72 hours, 7 days and 14 days after the onset of the disease. The sum of ST segment elevations, sum of Q wave amplitude and the sum of R wave amplitude in the leads showing signs of infarction were taken into account. The mean was calculated from the highest values of AspAT and AlAT. The haemodynamic, arrhythmic and other early and late complications occurring during the treatment were subjected to analysis; the per cent index of deaths in each group was also calculated. In the patients treated with streptokinase, in comparison to the patients treated with heparin and antiplatelet drugs, earliest stabilization was observed of the ECG pattern in the form of: reduction of ST segment elevation, reduction of R wave height, and formation of a stable Q wave. AspAT and AlAT values were highest in the group of patients treated with streptokinase in relation to the remaining groups of patients. Arrhythmic and haemodynamic complications occurred less frequently in the patients treated with streptokinase and heparin than in those treated with antiplatelet drugs. On the other hand, late and other early complications were observed less frequently in the patients treated with antiplatelet drugs. The mortality during hospitalization period was similar in individual groups of patients, being 7.2% for the patients treated with streptokinase, 7.5% for those treated with antiplatelet drugs, and 9% for those treated with heparin.
Jankowska
A
A
Studenckiego Koła Naukowego przy Klinice Kardiologii Ak. Med., Lublinie.
Sarachman
K
K
Drozd
J
J
Palusiński
R
R
Kudlicki
J
J
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001241:Aspirin / Q000627:therapeutic use; D018450:Disease Progression; D015716:Electrocardiography, Ambulatory; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006493:Heparin / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D013300:Streptokinase / Q000627:therapeutic use*; D015996:Survival Rate; D014810:Vitamin E / Q000627:therapeutic use
D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D014810:Vitamin E; D006493:Heparin; D013300:Streptokinase; D001241:Aspirin
Obraz kliniczny świezego zawału serca w zalezności od zastosowanego schematu leczenia farmakologicznego.